There’s a certain kind of book that masquerades as a memoir but is, in fact, a manifesto. Will Guidara’s Unreasonable Hospitality is one of those books. On its surface, it’s about restaurants—about Guidara’s tenure at Eleven Madison Park, about turning a fine-dining establishment into

In the grand cycle of corporate life, the pharmaceutical industry has mastered the art of layoffs while keeping its bottom line healthy. But where there’s crisis, there’s also opportunity—especially for the burgeoning species of career coaches. Once a niche profession, coaching has become a booming industry, thriving

Founders, let’s address a pervasive issue in biotech: the chronic neglect of financial metrics in pitch decks. Investors aren’t just looking for cutting-edge technology—they’re looking for a business. If your deck is a science lecture without a market strategy, you’re setting yourself up for

Michael Lewis has made a career of peering behind the velvet curtain of capitalism and calmly announcing: “It’s mostly cardboard.” With the eye of a journalist, the wit of a satirist, and the instincts of a trader, he’s unpacked some of the most complex systems in finance, sports,

The concepts of fat-tailed distributions and black swan events, as popularized by Nassim Nicholas Taleb in seminal work "The Black Swan: The Impact of the Highly Improbable" (2007), have indeed become critical for understanding risk and uncertainty in various fields, including finance and drug development. Taleb'

Drug discovery operates at the intersection of science, technology, and uncertainty. Despite advances in high-throughput screening, computational modeling, and clinical trial design, the industry remains vulnerable to black swan events—rare, high-impact phenomena that challenge traditional methodologies. The stakes are immense: late-stage clinical failures, regulatory surprises, and

If you’ve read this blog—ramblings, thought-leadership, or the digital equivalent of shouting into the void—you might be under the impression that I’m a grumpy old man. A professional curmudgeon. A pessimist with a newsletter. Well, I’ve got news: I’m not old. I am,

1. Pricing and Reimbursement Pressures 1.1 Early Pricing Negotiations * The New Reality: * Payers and HTA bodies, particularly in Europe, are scrutinizing clinical trial data earlier * Example: In the EU, HTA bodies involved in the Joint Clinical Assessment (JCA) may assess early efficacy data to predict pricing feasibility. Similarly, the

For biotech companies, the IPO is like a debutante ball—a grand public coming-out party where you hope to dazzle investors with your scientific brilliance and unshakable potential. In Europe, however, this glittering spectacle often ends up feeling like a poorly attended cocktail party where guests are reluctant to

Venture capital and private equity thrive on numbers—IRRs, TVPIs, MOICs—each acronym an attempt to quantify success in an industry where most real outcomes won’t be known for a decade. Naturally, fund managers need a way to show they’re winning, preferably before their portfolios actually deliver returns.